If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024. This is an important outcome because it now leads to another milestone for investors to look forward to, which is the initiation of the 36-week phase 2b study using this drug to treat these patients in Q4 of 2024. The scope of this biotech though is its ability to achieve rapid weight loss in a short amount of time a ...

Novartis is taking a more calculated and strategic approach to its growth. There are $200 billion reasons healthcare companies want to produce GLP-1 weight loss drugs. At that size, the market potential is huge, and the opportunities for revenue growth are plentiful. But it also means that competition will be fierce. And with some highly effective treatments already approved and available, the bar is set high for any new drug that wants to take a slice of that lucrative market. Not every company is jumping ...

Wisp debuts its first-ever exclusive over-the-counter weight-loss supplement, designed to promote women's metabolic health. Wisp introduces personalized, online consultations with access to four weight care solutions, including GLP-1 medications, to support women struggling with hormonal conditions such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis. With over 1.2 million patients, Wisp Now Also Bolsters its Menopause Solutions, Empowering Women Through All Major Stages of ...

The future of the weight loss market might not revolve around GLP-1 drugs. By now, nearly everyone has heard of the weight loss drugs targeted at the glucagon-like protein 1 (GLP-1) receptor, like Zepbound and Wegovy by Eli Lilly and Novo Nordisk, respectively. It's no surprise why they're household names; those medicines are bringing in billions of revenue every quarter, driving share prices up relentlessly along the way. However, GLP-1-based therapies aren't going to be the only option in the weight loss ...

GLP Group has announced the merger of its fund management business, GLP Capital Partners (GCP), with Ares Management Corporation, a leading alternative asset management company listed on the New York Stock Exchange. The merger includes GCP's international operations in Japan, the United States, Europe, Brazil, and Vietnam. The transaction is valued at a total of $5.2 billion, which consists of an initial consideration of $3.7 billion and a potential additional payout of up to $1.5 billion tied to performanc ...

Clinical studies highlight that Eli Lilly (LLY, Financial) and Novo Nordisk's (NVO) weight loss drugs result in significant lean body mass reduction, with 25% and 40% of weight loss attributed to muscle loss, respectively. In response, Regeneron (REGN) is researching a new drug aimed at mitigating muscle loss caused by weight loss medications. While drugs like Ozempic and Wegovy have spurred a "gold rush" in the pharmaceutical industry, George Yancopoulos, co-founder of Regeneron, warns of potential muscle ...

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets Licensed Product / Nation Patent Application Serial No. Title: Pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia containing microorganism transformed with cell surface display ...

Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, "TRIM," a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies. Tirzepatide, a dual GIP ...

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets Licensed Product / Nation Patent Application Serial No. Title: Pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia containing microorganism transformed with cell surface display ...